DPP4 inhibition (using the anti-diabetic medication, sitagliptin) in a pre-clinical syngeneic mouse model of breast cancer has been shown to increase CCL11 levels, eosinophil infiltration and improve tumor control and was synergistic with immune checkpoint inhibition [53]. Here, CCL11 is linked to breast carcinoma.